Decoy Therapeutics (DCOY) Change in Account Payables (2015 - 2026)
Decoy Therapeutics (DCOY) posted quarterly Change in Account Payables of -$4556.0 for Q1 2026, down 101.79% year-over-year from $254645.0 in Q1 2025, and up 99.62% quarter-over-quarter from -$1.2 million in Q4 2025.
Decoy Therapeutics (DCOY) Change in Account Payables (2015 - 2026) Analysis & Trends
Decoy Therapeutics (DCOY) has reported Change in Account Payables for 12 consecutive years, with -$4556.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables fell 101.79% year-over-year to -$4556.0; the TTM figure through Mar 2026 stood at -$1.4 million (down 398.58% YoY), while the FY2025 annual figure was -$1.2 million, down 449.27% from the prior year.
- Change in Account Payables improved to -$4556.0 in Q1 2026 per DCOY's latest filing, from -$1.2 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.1 million in Q4 2022 and bottomed at -$1.3 million in Q2 2023.
- Historically, Change in Account Payables has averaged -$104719.1 across 5 years, with a median of -$4556.0 in 2026.
- On a YoY basis, Change in Account Payables climbed as much as 317.54% in 2023 and fell as far as 1458.06% in 2023.
- Decoy Therapeutics' Change in Account Payables stood at $1.1 million in 2022, then slumped by 142.64% to -$485787.0 in 2023, then soared by 258.75% to $771193.0 in 2024, then slumped by 254.85% to -$1.2 million in 2025, then soared by 99.62% to -$4556.0 in 2026.
- Business Quant data shows DCOY's Change in Account Payables at -$4556.0 in Q1 2026, -$1.2 million in Q4 2025, and -$310839.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Decoy Therapeutics | 1.75 Mn | 1.75 Mn | - | -230,614.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -230,614.00 |
| Jun 30, 2026 | -230,614.00 |
| Mar 31, 2026 | -4,556.00 |
| Mar 31, 2026 | -4,556.00 |
| Dec 31, 2025 | -1.19 Mn |
| Dec 31, 2025 | -1.19 Mn |
| Sep 30, 2025 | -310,839.00 |
| Sep 30, 2025 | -310,839.00 |
| Jun 30, 2025 | 83,326.00 |
| Jun 30, 2025 | 83,326.00 |
| Mar 31, 2025 | 254,645.00 |
| Mar 31, 2025 | 254,645.00 |
| Dec 31, 2024 | 771,193.00 |
| Dec 31, 2024 | 771,193.00 |
| Sep 30, 2024 | -453,665.00 |
| Sep 30, 2024 | -453,665.00 |
| Jun 30, 2024 | -94,491.00 |
| Jun 30, 2024 | -94,491.00 |
| Mar 31, 2024 | 111,104.00 |
| Mar 31, 2024 | 111,104.00 |